Ian D Pavord

Nov 26, 2024 | thorax.bmj.com | Andrew Bush |Ian D Pavord

Andrew Bush, Paediatric Chest Physician, Imperial College and Royal Brompton Hospital, London, UKIan D Pavord, Respiratory Physician, Nuffield Department of Medicine, University of Oxford, Room 7400, Level 7EF, John Radcliffe Hospital, Oxford Conflict of Interest None declared

Oct 28, 2024 | tandfonline.com | Ian D Pavord |Robert Chan |Nicola Brown |Peter Howarth

AbstractObjectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma. Materials and methods This was a multicenter, Phase IIIb safety, open-label extension study of multiple prior studies assessing mepolizumab in addition to standard of care (Aug 2015 − Aug 2022).

Jul 11, 2024 | erj.ersjournals.com | Lee Hatter |Mark C. Holliday |Allie Eathorne |Ian D Pavord

FootnotesAuthor contributions: The Novel START study was designed by the authors prior to consultation with AstraZeneca. The global sponsor of the study, the Medical Research Institute of New Zealand, took overall responsibility for the study conduct, monitoring, and data management. AstraZeneca were not involved in the design, analysis, or drafting of this post hoc analysis, which was conducted and written independently by the study authors.

May 30, 2024 | healio.com | Richard Gawel |Kristen Dowd |Ian D Pavord

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The retrospective analysis included 26 clinical studies of approved indications. Treatment discontinuations for severe adverse events included 2% of the treatment and placebo groups alike.

May 30, 2024 | erj.ersjournals.com | Sanjay Ramakrishnan |Brett Montgomery |Ian D Pavord

FootnotesConflict of interest: S. Ramakrishnan declares salary support from the Charlies Foundation for Research, speaker honoraria from AstraZeneca and GlaxoSmithKline, and conference travel support from AstraZeneca. B. Montgomery declares an unpaid membership of the Guidelines Committee of the Australian Asthma Handbook, a project of the National Asthma Council Australia.